Waumans Yannick, Baerts Lesley, Kehoe Kaat, Lambeir Anne-Marie, De Meester Ingrid
Laboratory of Medical Biochemistry, Department of Pharmaceutical Sciences, University of Antwerp , Antwerp , Belgium.
Front Immunol. 2015 Aug 7;6:387. doi: 10.3389/fimmu.2015.00387. eCollection 2015.
Research from over the past 20 years has implicated dipeptidyl peptidase (DPP) IV and its family members in many processes and different pathologies of the immune system. Most research has been focused on either DPPIV or just a few of its family members. It is, however, essential to consider the entire DPP family when discussing any one of its members. There is a substantial overlap between family members in their substrate specificity, inhibitors, and functions. In this review, we provide a comprehensive discussion on the role of prolyl-specific peptidases DPPIV, FAP, DPP8, DPP9, dipeptidyl peptidase II, prolyl carboxypeptidase, and prolyl oligopeptidase in the immune system and its diseases. We highlight possible therapeutic targets for the prevention and treatment of atherosclerosis, a condition that lies at the frontier between inflammation and cardiovascular disease.
过去20年的研究表明,二肽基肽酶(DPP)IV及其家族成员参与了免疫系统的许多过程和不同病理过程。大多数研究都集中在DPPIV或其少数几个家族成员上。然而,在讨论其任何一个成员时,考虑整个DPP家族是至关重要的。家族成员在底物特异性、抑制剂和功能方面存在大量重叠。在这篇综述中,我们全面讨论了脯氨酰特异性肽酶DPPIV、FAP、DPP8、DPP9、二肽基肽酶II、脯氨酰羧肽酶和脯氨酰寡肽酶在免疫系统及其疾病中的作用。我们强调了预防和治疗动脉粥样硬化的可能治疗靶点,动脉粥样硬化是一种处于炎症和心血管疾病前沿的病症。